Related Experiment Video
Updated: Jul 16, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy
1Liver Research Unit, Chang Gung University, Taipei, Taiwan. liveryfl@so-net.net.tw
Insights
Chronic hepatitis B virus (HBV) infection requires effective suppression to prevent liver disease progression. Current therapies aim for sustained HBV replication control, but improved efficacy and reduced resistance are crucial goals.
Area of Science:
- Hepatology
- Virology
- Oncology
Background:
- Chronic hepatitis B virus (HBV) infection is a global health concern.
- HBV replication markers like HBeAg and HBV DNA indicate ongoing hepatitis activity and disease progression, including cirrhosis and hepatocellular carcinoma (HCC).
- Long-term studies show increased risk of progression with HBeAg positivity and HBV DNA levels above 10^4 copies/ml.
Purpose of the Study:
- To highlight the critical need for HBV elimination or sustained suppression.
- To discuss the role of antiviral therapies in reducing disease progression.
- To emphasize the limitations of current treatments and the goal of achieving high suppression rates with low resistance.
Main Methods:
- Review of long-term prospective studies in patients over 30 years of age.
- Analysis of HBV replication markers (HBeAg, HBV DNA) and their correlation with disease progression.
- Evaluation of existing therapies like interferon-alpha and direct antiviral agents.
Main Results:
- HBeAg seropositivity and HBV DNA levels (≥10^4 copies/ml) are associated with increased risk of liver cirrhosis and HCC.
- Antiviral therapy can reduce the risk of cirrhosis and disease worsening.
- Maintained suppression of HBV replication may decrease HCC progression.
Conclusions:
- Sustained suppression of HBV replication is essential for preventing hepatitis and halting disease progression.
- Current antiviral therapy efficacy is limited, necessitating the development of more effective treatments.
- The ultimate goal is achieving high rates of sustained HBV suppression with minimal drug resistance.
Abstract:
Chronic hepatitis B virus (HBV) infection is a serious health issue worldwide. The presence of HBV replication markers--hepatitis B e antigen (HBeAg) or HBV DNA--is associated with continuing hepatitis activity or intermittent hepatitis flares and subsequent disease progression, including hepatic decompensation and development of liver cirrhosis or hepatocellular carcinoma (HCC). Long-term (>10 years) prospective studies in patients >30 years of age have shown that HBeAg seropositivity is associated with increased risk of disease progression, and the risk of cirrhosis and HCC begins to increase at an HBV DNA level of 10(4) copies/ml. Therefore, elimination of HBV, or at least sustained or maintained suppression of HBV, is the key to reducing hepatitis and thereby halting or preventing disease progression. Therapy with interferon-alpha or a direct antiviral agent has been shown to reduce the risk of cirrhosis and prevent further disease worsening. In both the woodchuck hepatitis model and in HBV patients, maintained suppression of HBV replication by a direct antiviral agent may reduce the progression to HCC. However, the efficacy of current antiviral therapy is still far from satisfactory. The ability to achieve a high rate of sustained or maintained HBV suppression with a low risk of drug resistance would be the ultimate goal in the treatment of chronic HBV infection.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Viruses with RNA Genomes
Retrovirus Life Cycles
